Clinical trials have complex eligibility criteria.Always talk to your clinician about you’re interest in participating in a trial.Learn why
HP Version - Clinical trials have complex eligibility criteria.Always talk to your clinician about you’re interest in participating in a trial.Learn why
Optimise reading forHealth ProfessionalsPatients
RecruitingLast updated: 5 February 2024
Clinical summaryEligibiltyParticipating hospitalsSupport
Substudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03A is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced first line (1L) clear cell renal cell carcinoma (ccRCC). It will undertaken across two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents.
This trial is treating patients with clear cell renal cell carcinoma.
18 - 120
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03A
Share with email
Print this page
Clinical trials have complex eligibility criteria.
Ask your doctor if this trial could be right for you.
Tell us if you find this trial availability is not accurate.Report inaccuracy
Speak with someone who has cancer clinical trial experience.
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.
When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.
Thank you for helping us to increase accuracy of the trial. Our team will validate the information and update the information as soon as possible.